GlassScriptPhysician profile
Lori Ann Blackburn
NPI 1780791749
$6,274.92
in general payments reported to CMS, 2019-2025
42 companies · $639 in 2025
The $639 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,809 · 2022: $1,536 · 2023: $1,416 · 2024: $876 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,265.95 | 2021-2025 | |
| Novo Nordisk INC | $811.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $633.51 | 2021-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Astrazeneca Pharmaceuticals LP | $630.74 | 2021-2025 | Farxiga, Breztri, Flumist Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.77 | 2021-2025 | Jardiance |
| Pfizer INC. | $224.18 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $219.20 | 2021-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.58 | 2022-2025 | Caplyta |
| Inogen, INC. | $158.58 | 2022-2025 | Inogen At Home Stationary Concentrator |
| Biohaven Pharmaceuticals, INC. | $152.44 | 2021 | |
| Amgen INC. | $147.76 | 2021-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $136.30 | 2025 | Rexulti |
| Dexcom, INC. | $107.24 | 2021-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $98.23 | 2021 | |
| Axsome Therapeutics, INC. | $96.00 | 2023-2025 | Auvelity |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Blackburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.